


Automated synthesis and antimycobacterial activity of a series of 2-heteroarylcarboxamidrazones and related compounds


DAVID C. BILLINGTON, KATY J. TIMS AND DANIEL L. RATHBONE

Pharmaceutical Sciences Institute, Aston University, Aston Triangle, Birmingham B4 7ET

Some N^1 -benzylideneheteroarylcarboxamidrazones (1) are known to have antimycobacterial activity [Mamolo et al (1992, 1993a, 1993b), Mamolo & Vio (1996)].




The key structural features which were identified as associated with antimycobacterial activity are as follows: the amidrazone moiety is to be connected to a pyridine-based group and hydrophobic substituents on the benzylidene group are essential, preferably at the 2-position. In an ongoing programme concerning the discovery of new antimycobacterial agents we synthesised and tested a range of heteroarylcarboxamidrazones against *M. fortuitum* reference strain NCTC 10394 in a rapid screen as a model for *M. tuberculosis*. (Billington *et al* 1998). A diverse range of substituents had been included in the aryl hydrazone portion of the amidrazones (1).



From this set compounds 2-5 were the most active. It appears that the ortho-substituted benzylidene fragment must have the possibility to be essentially

planar. The major departure from this trend is the most active compound (2) which features a substituted benzylidene which is not only a para-substituted but also non-planar. Compounds 2-5 were used as lead structures for the preparation of further focused libraries. Thus, matrices of functionalised carboxamidrazones and hydrazines were combined with a range of carbonyl components in an automated manner, to give the corresponding N^1 -benzylidenehydrazones and hydrazones. The products, which were usually crystalline, were isolated by robotic trituration with a suitable solvent and characterised by automated APCI-MS. The crude materials were screened against *M. fortuitum*. Compounds exhibiting a zone of inhibition of the organism on an agar plate were purified, where necessary, and MICs were obtained in Middlebrook 7H9 broth.

In summary, changing from the 2-pyridylcarboxamidrazone series to the 4-pyridylcarboxamidrazone series gave virtually identical activity profiles over a wide range isomeric structures. The most active compounds discovered were an isomeric pair 6 and 7. In contrast, changing from 2-pyridylcarboxamidrazones to 2-pyridylhydrazones resulted in a complete loss of activity.



Billington et al (1998), *Drug Design and Discovery*, *in press*.
 Mamolo M.G. et al, (1992), *Farmaco*, 1055-1066
 Mamolo M.G. et al, (1993a), *Farmaco*, 529-538
 Mamolo M.G. et al, (1993b), *J.Chemotherapy*, 164-167
 Mamolo M.G and Vio L., (1996) *Farmaco*, 65-70